- Home
- SAND vs XNCR Comparison
SAND vs XNCR Comparison
Compare SAND & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- XNCR
- Stock Information
- Founded
- SAND 2007
- XNCR 1997
- Country
- SAND Canada
- XNCR United States
- Employees
- SAND N/A
- XNCR N/A
- Industry
- SAND
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- SAND
- XNCR Health Care
- Exchange
- SAND NYSE
- XNCR Nasdaq
- Market Cap
- SAND 1.5B
- XNCR 1.5B
- IPO Year
- SAND N/A
- XNCR 2013
- Fundamental
- Price
- SAND $6.01
- XNCR $20.85
- Analyst Decision
- SAND Buy
- XNCR Strong Buy
- Analyst Count
- SAND 4
- XNCR 9
- Target Price
- SAND $9.13
- XNCR $34.67
- AVG Volume (30 Days)
- SAND 2.3M
- XNCR 661.1K
- Earning Date
- SAND 11-04-2024
- XNCR 11-05-2024
- Dividend Yield
- SAND 0.98%
- XNCR N/A
- EPS Growth
- SAND N/A
- XNCR N/A
- EPS
- SAND 0.10
- XNCR N/A
- Revenue
- SAND $170,007,000.00
- XNCR $133,618,000.00
- Revenue This Year
- SAND $0.85
- XNCR N/A
- Revenue Next Year
- SAND $8.68
- XNCR $63.76
- P/E Ratio
- SAND $60.05
- XNCR N/A
- Revenue Growth
- SAND N/A
- XNCR 17.84
- 52 Week Low
- SAND $3.96
- XNCR $15.31
- 52 Week High
- SAND $6.29
- XNCR $26.84
- Technical
- Relative Strength Index (RSI)
- SAND 59.66
- XNCR 62.61
- Support Level
- SAND $5.38
- XNCR $16.14
- Resistance Level
- SAND $6.29
- XNCR $21.65
- Average True Range (ATR)
- SAND 0.17
- XNCR 1.15
- MACD
- SAND 0.06
- XNCR 0.45
- Stochastic Oscillator
- SAND 68.68
- XNCR 85.57
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.